StoneX Group Inc. Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

StoneX Group Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 40.5% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 42,849 shares of the company's stock after buying an additional 12,359 shares during the quarter. StoneX Group Inc.'s holdings in Johnson & Johnson were worth $6,197,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Oregon Pacific Wealth Management LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $949,000. Horan Securities Inc. lifted its holdings in Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after acquiring an additional 90 shares during the period. Strategic Financial Concepts LLC boosted its position in Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock worth $501,000 after purchasing an additional 1,271 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $69,859,000. Finally, Quantinno Capital Management LP increased its position in shares of Johnson & Johnson by 29.0% during the 3rd quarter. Quantinno Capital Management LP now owns 219,599 shares of the company's stock valued at $35,588,000 after purchasing an additional 49,307 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Remove Ads

Johnson & Johnson Price Performance

JNJ traded down $12.60 during trading on Tuesday, hitting $153.25. 23,293,291 shares of the company traded hands, compared to its average volume of 7,720,065. The company has a market cap of $369.30 billion, a PE ratio of 23.04, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock's 50-day simple moving average is $159.16 and its two-hundred day simple moving average is $155.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.29 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of research reports. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Finally, StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.